GLUE Chief Medical Officer Filip Janku Sells $138K of Stock

Filip Janku Sells 6,000 Shares of Monte Rosa Therapeutics

Filip Janku, the Chief Medical Officer of Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), sold 6,000 shares of the company on June 29, 2026. The transaction was valued at $137,700, with the shares sold at a price of $22.95. This sale was carried out under a Rule 10b5-1 trading plan, which is a pre-set schedule that allows insiders to sell a specific number of shares at a predetermined time.

This transaction followed other activity by Janku on the same day. According to regulatory filings, Janku also acquired 6,000 shares at a price of $7.56 on June 29, 2026. This mirrors a similar acquisition he made just a few days earlier on June 23, 2026, when he also picked up 6,000 shares at that same $7.56 price point.

Monte Rosa Therapeutics Stock Performance

On Wednesday, shares of Monte Rosa Therapeutics were trading at $24.20. The stock has shown significant strength recently, trading much closer to its 52-week high of $25.77 than its 52-week low of $6.25. The current price is also sitting comfortably above the 50-day moving average of $16.92 and the 200-day moving average of $18.43. With a market capitalization of roughly $1.05 billion, the company's stock has maintained upward momentum as it approaches its next earnings date.

Recent Earnings Data

In its most recent financial reports, Monte Rosa Therapeutics reported revenue of $28.73 million. However, the company is still in its clinical stages and is not yet profitable, reporting a return on equity of negative 42.6% and an earnings per share (EPS) of -$1.75. Because the company is not currently earning a profit, it does not have a traditional P/E ratio. Investors are looking toward November 5, 2026, for the next scheduled earnings update to see how the company's pipeline is progressing.

Insider Buying and Selling at Monte Rosa Therapeutics, Inc.

Filip Janku isn't the only insider who has been active lately. On June 29, 2026, Anthony Manning also engaged in both buying and selling activity. Manning purchased 10,000 shares at $4.16 and sold 10,000 shares at $23.11, resulting in a transaction value of $231,100 for the sale. These moves by top executives often happen around the same time due to the vesting of stock options or the execution of planned trading programs.

Analysts Set New Price Targets

Wall Street remains optimistic about the company's future. On October 5, 2026, H.C. Wainwright & Co. reiterated a Buy rating with a $25.00 price target. This followed their initial Buy rating set earlier in October. Other firms have also weighed in, including Wedbush, which reiterated an Outperform rating and a $27.00 price target on September 9, 2026. Guggenheim maintained a Buy rating on August 25, 2026, with a target of $28.00. Currently, six analysts follow the stock, and the consensus is a Strong Buy with a mean price target of $28.50.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology firm based in Boston that focuses on creating precision medicines. They specialize in "molecular glue degraders," which are small molecules designed to use the body’s own systems to break down specific proteins that cause disease. Their work spans across oncology, autoimmune diseases, and inflammatory conditions. The company has already formed strategic partnerships with major pharmaceutical players like Roche and Novartis to help advance its discovery engine.

What's Ahead for Monte Rosa Therapeutics, Inc.

The recent insider sales by Filip Janku and Anthony Manning are part of a broader pattern of executive activity at the company this summer. While these sales were conducted at prices near the stock's yearly highs, analyst sentiment remains firmly in the Buy camp. Investors will likely keep a close eye on the November 5, 2026, earnings call for updates on the company's clinical trials and cash position. As with all insider filings, these reports show past transactions and might not represent how these executives feel about the stock today.